Retatrutide
Next-generation triple agonist
Overview
Triple GLP-1/GIP/glucagon receptor agonist. Phase 3 clinical trials show 24%+ body weight reduction — exceeding both semaglutide and tirzepatide in head-to-head comparisons. Currently available through select compounding pharmacies pending full FDA approval.
Key Benefits
- ✓24%+ weight loss in Phase 3 trials
- ✓Triple GLP-1/GIP/glucagon receptor mechanism
- ✓Superior efficacy vs semaglutide and tirzepatide
- ✓Significant metabolic improvements
- ✓Strong appetite suppression
Dosing Protocol
How to Use
Still in Phase 3 trials as of 2026. Available through select compounding pharmacies. Consult a physician for access — do not self-prescribe.
Titration Schedule
Follow this stepwise dose advancement. Never skip a step.
- Week 11mgStarting dose
- Week 54mgTitration 1
- Week 98mgTitration 2
- Week 1312mgMaintenance
The Science
This compound has FDA-backed clinical evidence — review the trial data and prescribing information below.
Get a Prescription
Prescription Required
TelehealthGLP-1 medications require a prescription. Connect with a licensed telehealth provider to get started.
STACK does not sell, prescribe, or dispense medications.
Track Retatrutide with the STACK app
Set dose reminders, monitor your supply, and ask AI questions about your protocol — all in one place.
All content is for informational purposes only. Peptides are research compounds. Consult a licensed healthcare provider before starting any protocol.
STACK may earn a commission when you purchase through our links at no extra cost to you. This never influences our recommendations — we only feature vendors with verified third-party testing and established quality standards.